Role of FDG PET-CT in detecting recurrence in patients with uterine sarcoma: Comparison with conventional imaging

Nuclear Medicine Communications

Volumn 33, Issue 2, 2012, Pages 185-190

  Sharma, Punit ^a   Kumar, Rakesh ^a   Singh, Harmandeep ^a   Jeph, Sunil ^a   Sharma, Jai Bhagwan ^a   Jain, Sunesh Kumar ^a   Sharma, Daya Nand ^a   Bal, Chandrashekhar ^a   Malhotra, Arun ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

18F fluorodeoxyglucose; PET CT; recurrence; uterine sarcoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ABDOMEN; ADULT; ARTICLE; CANCER EPIDEMIOLOGY; CANCER RECURRENCE; CARCINOSARCOMA; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ECHOGRAPHY; ENDOMETRIUM SARCOMA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEIOMYOSARCOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; PELVIS; PHYSICIAN; SENSITIVITY AND SPECIFICITY; THORAX; UTERUS SARCOMA;

CONTRAST MEDIA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SARCOMA; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; UTERINE NEOPLASMS;

EID: 84855194900     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32834e41a6     Document Type: Article

References (17)

1. Major FJ, Blessing JA, Silverberg SG, Morrow CP, Creasman WT, Currie JL, et al. Prognostic factors in early stage uterine sarcoma: a Gynecologic Oncology Group study. Cancer 1993; 7:1702-1709. (Pubitemid 23056094)
2. Giuntoli RL II, Metzinger DS, DiMarco CS, Cha SS, Sloan JA, Keeney GL, Gostout BS. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 2003; 89:460-469. (Pubitemid 36687793)
3. World Health Organization. Classification of tumours. In: Tavassoli FA, Devilee P, editors. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press. 2003; pp. 13-59.
4. Sutton G, Brunetto VL, Kilgore L, Soper JT, McGehee R, Olt G, et al. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 2000; 79:147-153.
5. Kinkel K, Ariche M, Tardivon AA, Spatz A, Castaigne D, Lhomme C, Vanel D. Differentiation between recurrent tumor and benign conditions after treatment of gynecologic pelvic carcinoma: value of dynamic contrast enhanced subtraction MR imaging. Radiology 1997; 204:55-63. (Pubitemid 27281709)
6. Siegelman ES, Outwater EK. Tissue characterization in the female pelvis by means of MR imaging. Radiology 1999; 212:5-18. (Pubitemid 29302505)
7. Connor JP, Andrews JI, Anderson B, Buller RE. Computed tomography in endometrial carcinoma. Obstet Gynecol 2000; 95:692-696. (Pubitemid 30210053)
8. Yen TC, Ng KK, Ma SY, Chou HH, Tsai CS, Hsueh S, et al. Value of dual-phase 2-fluoro-2-deoxy-D-glucose positron emission tomography in cervical cancer. J Clin Oncol 2003; 21:3651-3658. (Pubitemid 46594059)
9. Zimny M, Siggelkow W, Schroder W, Nowak B, Biemann S, Rath W, Buell U. 2-Fluorine-18-fluoro-2-deoxy-D-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol 2001; 83:310-315. (Pubitemid 33033072)
10. Kitajima K, Murakami K, Yamasaki E, Domeki Y, Kaji Y, Morita S, et al. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer: comparison with PET and enhanced CT. Eur J Nucl Med Mol Imaging 2009; 36:362-372.
11. Nagamatsu A, Umesaki N, Li L, Tanaka T. Use of 18F-fluorodeoxyglucose positron emission tomography for diagnosis of uterine sarcomas. Oncol Rep 2010; 23:1069-1076.
12. Sung PL, Chen YJ, Liu RS, Shieh HJ, Wang PH, Yen MS, et al. Whole-body positron emission tomography with 18F-fluorodeoxyglucose is an effective method to detect extra-pelvic recurrence in uterine sarcomas. Eur J Gynaecol Oncol 2008; 29:246-251. (Pubitemid 351744486)
13. Park JY, Kim EN, Kim DY, Suh DS, Kim JH, Kim YM, et al. Role of PET or PET/CT in the post-therapy surveillance of uterine sarcoma. Gynecol Oncol 2008; 109:255-262.
14. Ho KC, Lai CH, Wu TI, Ng KK, Yen TC, Lin G, et al. 18F-fluorodeoxyglucose positron emission tomography in uterine carcinosarcoma. Eur J Nucl Med Mol Imaging 2008; 35:484-492. (Pubitemid 351661666)
15. Rebollo Aguirre AC, Ramos Font C, Bellón Guardia ME, Cabello Garćia D, Gallego Peinado M, Rodŕiguez Fernández A, Llamas Elvira JM. Positron emission tomography with 18F-fluorodeoxyglucose in patients with uterine sarcoma. Rev Esp Med Nucl 2007; 26:189-195. (Pubitemid 47242180)
16. Murakami M, Tsukada H, Shida M, Watanabe M, Maeda H, Koido S, et al. Whole-body positron emission tomography with F-18 fluorodeoxyglucose for detection of recurrence in uterine sarcomas. Int J Gynecol Cancer 2006; 16:854-860.
17. Kluetz PG, Meltzer CC, Villemagne VL, Kinahan PE, Chander S, Martinelli MA, Townsend DW. Combined PET/CT imaging in oncology. Impact on patient management. Clin Positron Imaging 2000; 3:223-230.